Last reviewed · How we verify

Laboratorios Silanes S.A. de C.V. — Portfolio Competitive Intelligence Brief

Laboratorios Silanes S.A. de C.V. pipeline: 1 marketed, 0 filed, 16 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 16 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
metformin/glimepiride combination metformin/glimepiride combination marketed Biguanide/Sulfonylurea combination AMP-activated protein kinase (AMPK) pathway; ATP-sensitive potassium channels (KATP) Endocrinology/Diabetes
Etoricoxib + Cyanocobalamin fixed dose Etoricoxib + Cyanocobalamin fixed dose phase 3 COX-2 selective inhibitor + vitamin B12 supplement COX-2 enzyme; cyanocobalamin (B12 cofactor) Pain management / Rheumatology
Etoricoxib + Tizanidine fixed dose Etoricoxib + Tizanidine fixed dose phase 3 COX-2 selective inhibitor + centrally-acting muscle relaxant COX-2 enzyme; alpha-2 adrenergic receptor Pain Management / Musculoskeletal Disorders
Etoricoxib fixed dose Etoricoxib fixed dose phase 3 Selective COX-2 inhibitor (coxib) COX-2 (Cyclooxygenase-2) Rheumatology / Pain Management
Monotherapy Etoricoxib Monotherapy Etoricoxib phase 3 Selective COX-2 inhibitor (coxib) COX-2 (Cyclooxygenase-2) Rheumatology / Pain Management
Sibutramine-Metformin Sibutramine-Metformin phase 3 Combination antiobesity and antidiabetic agent Norepinephrine transporter (NET), serotonin transporter (SERT); AMP-activated protein kinase (AMPK) Endocrinology / Obesity / Diabetes
Celecoxi + Acetaminophen Celecoxi + Acetaminophen phase 3 NSAID + Analgesic combination (COX-2 selective inhibitor + acetaminophen) COX-2 enzyme; prostaglandin synthesis pathway Pain Management / Rheumatology
Celecoxib + Acetaminohen Celecoxib + Acetaminohen phase 3 NSAID + analgesic combination COX-2 (celecoxib); prostaglandin synthesis pathway (acetaminophen) Pain Management / Rheumatology
Dexketoprofen/Vitamin B Dexketoprofen/Vitamin B phase 3 NSAID with vitamin supplement COX-1, COX-2 Pain Management / Rheumatology
Losartan + hydrochlorothiazide in fixed dose Losartan + hydrochlorothiazide in fixed dose phase 3 Angiotensin II receptor antagonist + thiazide diuretic combination AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter Cardiovascular
Celecoxib + Vitamin B fixed dose Celecoxib + Vitamin B fixed dose phase 3 Selective COX-2 inhibitor + B vitamin complex COX-2 (cyclooxygenase-2) Rheumatology / Pain Management
Desloratadine / Betamethasone in fixed dose Desloratadine / Betamethasone in fixed dose phase 3 Antihistamine / Corticosteroid combination H1 receptor / Glucocorticoid receptor Immunology / Allergy

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chinese University of Hong Kong · 1 shared drug class
  2. EMS · 1 shared drug class
  3. Ferring Ventures Limited · 1 shared drug class
  4. Jiangsu XinChen-Techfields Pharma Co., LTD. · 1 shared drug class
  5. Merck Sharp & Dohme LLC · 1 shared drug class
  6. National Eye Institute (NEI) · 1 shared drug class
  7. Novartis · 1 shared drug class
  8. Asker & Baerum Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Laboratorios Silanes S.A. de C.V.:

Cite this brief

Drug Landscape (2026). Laboratorios Silanes S.A. de C.V. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/laboratorios-silanes-s-a-de-c-v. Accessed 2026-05-17.

Related